Press ReleasesIndustrialsDanish Aerospace Company to support development of a new area: 3D Bone Quality Imaging system for space By globenewswire August 1, 2025 1 0 Danish Aerospace Company to support development of a new area: 3D Bone Quality Imaging system for space COMPANY ANNOUNCEMENT Source: https://www.globenewswire.com/news-release/2025/08/01/3125602/0/en/Danish-Aerospace-Company-to-support-development-of-a-new-area-3D-Bone-Quality-Imaging-system-for-space.html TagsaerospaceannouncementbonecompanyCopenhagen:DACASdevelopmentDK0061140407FORimagingnewsqualityreleasesourcespacesupportsystem Previous articleYutong Van Proves Its Mettle on Ghana’s Road: Reliability, Fuel-Efficiency Shine and ComfortNext articleUAE’s Largest Bank FAB Relocates to New London Address Cementing 48-Year Legacy in the UK globenewswire Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign June 7, 2026 GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders June 7, 2026 Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health June 7, 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while... June 7, 2026 Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide June 7, 2026 Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide June 7, 2026 Recent News Unlocking the Americas: Air Canada and Abra Group Sign Memorandum to Expand Travel and Connectivity between Canada, Latin America and Beyond Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting... Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide